Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

173
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
173
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

368
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
368
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

260
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
260
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

5.1K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
5.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

483
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
483
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advice on the safe introduction and continued use of isotretinoin in acne in the U.K. 2010.

The British journal of dermatology·2011
Same author

Transfer of orbital angular momentum from a stressed fiber-optic waveguide to a light beam.

Applied optics·2008
Same author

Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne.

Health technology assessment (Winchester, England)·2004
Same author

NBCCS secondary to an interstitial chromosome 9q deletion.

Clinical and experimental dermatology·2004
Same author

Diagnosing bacterial skin infections.

The Practitioner·2000
Same author

Correlation of clinical, endocrine and molecular abnormalities with in vivo responses to high-dose testosterone in patients with partial androgen insensitivity syndrome.

Clinical endocrinology·1997

Related Experiment Videos

Dermatomyositis induced by penicillamine

N B Simpson, J R Golding

    Acta Dermato-Venereologica
    |January 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    D-Penicillamine therapy for rheumatoid arthritis may induce dermatomyositis. This drug-induced dermatomyositis resolved after discontinuing D-Penicillamine, with no signs of cancer.

    Related Experiment Videos

    Area of Science:

    • Rheumatology
    • Dermatology
    • Pharmacology

    Background:

    • Rheumatoid arthritis (RA) is a chronic autoimmune disease.
    • D-Penicillamine is a chelating agent used to treat RA.
    • Drug-induced dermatomyositis is a rare but serious adverse effect.

    Observation:

    • A 50-year-old woman with RA developed dermatomyositis while on D-Penicillamine.
    • Comprehensive investigations ruled out any underlying neoplasia.
    • Dermatomyositis symptoms improved significantly after D-Penicillamine was stopped.

    Findings:

    • D-Penicillamine-induced dermatomyositis is a potential complication of RA treatment.
    • Discontinuation of D-Penicillamine led to remission of dermatomyositis.
    • The absence of neoplasia suggests a direct drug-related etiology.

    Implications:

    • Clinicians should consider drug-induced dermatomyositis in RA patients on D-Penicillamine presenting with characteristic symptoms.
    • Early recognition and withdrawal of the causative agent are crucial for favorable outcomes.
    • This case highlights the importance of pharmacovigilance in managing autoimmune diseases.